Workiva Announces Julie Iskow as Chief Executive Officer
22.2.2023 00:15:00 EET | Business Wire | Press release
Workiva Inc. (NYSE: WK), the company powering transparent reporting for a better world, announced today that Julie Iskow, current President and Chief Operating Officer, has been appointed to succeed Marty Vanderploeg as Chief Executive Officer, effective April 1, 2023. Vanderploeg is stepping down as CEO, but will remain with the company in the role of Non-Executive Chair of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005356/en/
Workiva Inc. (NYSE: WK) Announces Julie Iskow as Chief Executive Officer (Photo: Business Wire)
Current Board Chair and prospective Lead Independent Director Dave Mulcahy said, “The Board is delighted to appoint Julie Iskow to Chief Executive. She is a strong, respected, and values-driven leader with an impressive and proven track record of delivering consistent high-quality performance through her relentless commitment to our customers and to our people. Julie has played an instrumental role in Workiva’s success over the last three years. She is an engineer, technologist, and strategic operator, whose innovation-first mindset has created a differentiated product offering and sustainable rigor around Workiva’s platform and solutions. The Board is confident in Julie’s ability to lead Workiva through its next stage of growth.”
Of her new role, Iskow said, “Workiva is one of the most relevant and innovative technology companies of our time. We have a transformative platform, unbridled potential, and an enduring foundation on which to build our future. I consider it a distinct privilege to succeed Marty and work with our incredibly talented team to move Workiva’s legacy forward into our next phase of growth and impact.”
Mulcahy said, “We would like to thank Marty for his steadfast leadership. During his tenure, he transformed Workiva into the leading multi-solution platform company for assured integrated business reporting, serving 5,600 customers across the globe. Marty has been an exceptional leader for Workiva, championing an employee culture of progress, product innovation, customer focus, and achieving strong shareholder value. We look forward to working with him in his expanded Board leadership role.”
“As a co-founder of Workiva, I have had the good fortune of working with a talented team for the past 15 years, five of those as CEO,” said Vanderploeg. “Now is the right time for me, and for Workiva, to make this change. Since day one of Julie’s arrival, she’s made our organization better. Julie has spent the past three years thoughtfully building and shaping our remarkable leadership team and operational strategy as we progress toward a long-term goal of $1 billion in revenue. I look forward to supporting her in my new role as Non-Executive Chair.”
About Julie Iskow
Julie Iskow joined Workiva in 2019 as EVP and Chief Operating Officer. She has extensive experience scaling enterprise SaaS companies with strong, profitable growth and has a robust background in product development and optimizing operations. Iskow was promoted to President and Chief Operating Officer in March 2022 and has been overseeing day-to-day operations with global responsibility for technology, product, sales, partners, marketing, services, and customer and partner experience. This transition allows her and the Workiva team to continue with their excellence in execution.
Before joining Workiva, Iskow served as EVP and Chief Technology Officer at Medidata Solutions, creator of cutting-edge SaaS technology and analytics solutions for life sciences. Prior to Medidata, she was the Senior Vice President of Product Development and Chief Information Officer at WageWorks, a SaaS platform for consumer directed benefits solutions. Before WageWorks, she spent over a decade in engineering and technology leadership positions, responsible for automation and robotics software used in high-tech manufacturing.
She currently serves on the board of directors of Workiva Inc. and Five9, a leading provider of cloud software for contact centers. She has a bachelor of science degree from the University of California, Berkeley and a master of science degree from the University of California, Davis.
About Workiva
Workiva Inc. (NYSE:WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva
Follow Workiva on Twitter: www.twitter.com/workiva
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005356/en/
Contact information
Investor Inquiries:
Mike Rost
investor@workiva.com
(515) 663-4493
Media Inquiries:
Darcie Brossart
press@workiva.com
(515) 663-4471
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom